Gain-of-function mutations and immunodeficiency: At a loss for proper tuning of lymphocyte signaling

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 6, 2015, Pages 533-538

  Arjunaraja, Swadhinya ^a   Snow, Andrew L ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Activated PI 3K syndrome; B cell expansion with NF B and T cell anergy; CARD11; PASLI; Phosphoinositide 3 kinase

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CLONAL ANERGY; GAIN OF FUNCTION MUTATION; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL DIFFERENTIATION; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; CELL DIFFERENTIATION; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOCYTES; MOLECULAR TARGETED THERAPY; MUTATION; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84947018491     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000217     Document Type: Review

References (51)

1. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162.
2. Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol 2013;13:635-648.
3. Boisson B, Quartier P, Casanova JL. Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. Curr Opin Immunol 2015;32:90-105.
4. Brohl AS, Stinson JR, Su HC, et al. Germline CARD11 mutation in a patient with severe congenital B cell lymphocytosis. J Clin Immunol 2014;35:32-46.
5. Buchbinder D, Stinson JR, Nugent DJ, et al. Mild B-cell lymphocytosis in patients with a CARD11 C49Y mutation. J Allergy Clin Immunol 2015.
6. Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012;209:2247-2261.
7. Blonska M, Lin X. CARMA1-mediated NF-kB and JNK activation in lymphocytes. Immunol Rev 2009;228:199-211.
8. Hamilton KS, Phong B, Corey C, et al. T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Sci Signal 2014;7:ra55.
9. Thome M, Charton JE, Pelzer C, Hailfinger S. Antigen receptor signaling to NF-kB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2010;2:a003004.
10. Vallabhapurapu S, Karin M. Regulation and function of NF-kB transcription factors in the immune system. Ann Rev Immunol 2009;27:693-733.
11. Lamason RL, McCully RR, Lew SM, Pomerantz JL. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry 2010;49:8240-8250.
12. McCully RR, Pomerantz JL. The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association. Molec Cell Biol 2008;28:5668-5686.
13. Paul S, Traver MK, Kashyap AK, et al. T cell receptor signals to NF-kappaB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome. Sci Signal 2014;7:ra45.
14. Qiao Q, Yang C, Zheng C, et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Mol Cell 2013;51:766-779.
15. Rawlings DJ, Sommer K, Moreno-Garcia ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006;6:799-812.
16. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-1679.
17. Chan W, Schaffer TB, Pomerantz JL. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival. Molec Cellul Biol 2013;33:429-443.
18. Sasaki Y, Derudder E, Hobeika E, et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006;24:729-739.
19. Staudt LM. Oncogenic activation of NF-kB. Cold Spring Harb Perspect Biol 2010;2:a000109.
20. Courtois G, Smahi A, Reichenbach J, et al. A hypermorphic IkBa mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003;112:1108-1115.
21. Janssen R, Van Wengen A, Hoeve MA, et al. The same IkBa mutation in two related individuals leads to completely different clinical syndromes. J Exp Med 2004;200:559-568.
22. Lopez-Granados E, Keenan JE, Kinney MC, et al. A novel mutation in NFKBIA/IKBA results in a degradation-resistant N-truncated protein and is associated with ectodermal dysplasia with immunodeficiency. Hum Mutat 2008;29:861-868.
23. McDonald DR, Mooster JL, Reddy M, et al. Heterozygous N-terminal deletion of IkBa results in functional nuclear factor kappaB haploinsufficiency, ectodermal dysplasia, and immune deficiency. J Allergy Clin Immunol 2007;120:900-907.
24. Schimke LF, Rieber N, Rylaarsdam S, et al. A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy. J Clin Immunol 2013;33:1088-1099.
25. Yoshioka T, Nishikomori R, Hara J, et al. Autosomal dominant anhidrotic ectodermal dysplasia with immunodeficiency caused by a novel NFKBIA mutation, p. Ser36Tyr, presents with mild ectodermal dysplasia and noninfectious systemic inflammation. J Clin Immunol 2013;33:1165-1174.
26. Krishna S, Xie D, Gorentla B, et al. Chronic activation of the kinase IKKb impairs T cell function and survival. J Immunol 2012;189:1209-1219.
27. Jeelall YS, Wang JQ, Law HD, et al. Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. J Exp Med 2012;209:1907-1917.
28. Hailfinger S, Lenz G, Thome M. Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase. Curr Opin Chem Biol 2014;23:47-55.
29. Turvey SE, Durandy A, Fischer A, et al. The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency. J Allergy Clin Immunol 2014;134:276-284.
30. Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 2013;342:866-871.
31. Jou ST, Chien YH, Yang YH, et al. Identification of variations in the human phosphoinositide 3-kinase p110delta gene in children with primary B-cell immunodeficiency of unknown aetiology. Int J Immunogenet 2006;33:361-369.
32. Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI (3) K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15:88-97.
33. Okkenhaug K, Turner M, Gold MR. PI3K signaling in B cell and T cell biology. Front Immunol 2014;5:557.
34. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
35. Sullivan JA, Kim EH, Plisch EH, et al. FOXO3 regulates CD8 T cell memory by T cell-intrinsic mechanisms. PLoS Pathogens 2012;8:e1002533.
36. Sullivan JA, Kim EH, Plisch EH, Suresh M. FOXO3 regulates the CD8 T cell response to a chronic viral infection. J Virol 2012;86:9025-9034.
37. Suzuki A, Kaisho T, Ohishi M, et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003;197:657-667.
38. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001;14:523-534.
39. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-929.
40. Wu H, Shekar SC, Flinn RJ, et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110a and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A 2009;106:20258-20263.
41. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008;105:2652-2657.
42. Burke JE, Perisic O, Masson GR, et al. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110a (PIK3CA). Proc Natl Acad Sci U S A 2012;109:15259-15264.
43. Mandelker D, Gabelli SB, Schmidt-Kittler O, et al. A frequent kinase domain mutation that changes the interaction between PI3Ka and the membrane. Proc Natl Acad Sci U S A 2009;106:16996-17001.
44. Van Der Windt GJ, Pearce EL. Metabolic switching and fuel choice during Tcell differentiation and memory development. Immunol Rev 2012;249:27-42.
45. Deau MC, Heurtier L, Frange P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest 2014;124:3923-3928.
46. Lucas CL, Zhang Y, Venida A, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med 2014;211:2537-2547.
47. Kracker S, Curtis J, Ibrahim MA, et al. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome. J Allergy Clin Immunol 2014;134:233-236.
48. Conley ME, Dobbs AK, Quintana AM, et al. A gamma globulinemia and absent B lineage cells in a patient lacking the p85a subunit of PI3K. J Exp Med 2012;209:463-470.
49. Greil J, Rausch T, Giese T, et al. Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency. J Allergy Clin Immunol 2013;131:1376-1383. e3.
50. Stepensky P, Keller B, Buchta M, et al. Deficiency of caspase recruitment domain family, member 11(CARD11), causes profound combined immunodeficiency in human subjects. J Allergy Clin Immunol 2013;131:477-485; e1.
51. Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012;366:330-338.